obinutuzumab: Intravenous infusion of 1000 mg of obinutuzumab (genetical recombination) at a time.

2 trials

Sponsors

Tanaka Yoshiya, Yoshiya Tanaka

Conditions

Lupus Nephritissystemic lupus erythematosus

Phase 3

A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

Active, not recruitingJPRN-jRCT2011210059

Tanaka YoshiyaLupus Nephritis

Start: 2022-06-24Target: 24Updated: 2026-06-29

A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Active, not recruitingJPRN-jRCT2071230031

Yoshiya Tanakasystemic lupus erythematosus

Start: 2023-10-10Target: 24Updated: 2026-06-29